These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 11850248

  • 21. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
    Pestova E, Millichap JJ, Noskin GA, Peterson LR.
    J Antimicrob Chemother; 2000 May; 45(5):583-90. PubMed ID: 10797078
    [Abstract] [Full Text] [Related]

  • 22. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
    Pan XS, Fisher LM.
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
    [Abstract] [Full Text] [Related]

  • 23. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
    Richter SS, Heilmann KP, Beekmann SE, Miller NJ, Rice CL, Doern GV.
    Clin Infect Dis; 2005 Jan 15; 40(2):225-35. PubMed ID: 15655739
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin.
    Stewart BA, Johnson AP, Woodford N.
    J Med Microbiol; 1999 Dec 15; 48(12):1103-1106. PubMed ID: 10591164
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S, Van Heirstraeten L, Lammens C, Chapelle S, Goossens H.
    J Antimicrob Chemother; 2009 May 15; 63(5):886-94. PubMed ID: 19279051
    [Abstract] [Full Text] [Related]

  • 36. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?
    Doern GV, Richter SS, Miller A, Miller N, Rice C, Heilmann K, Beekmann S.
    Clin Infect Dis; 2005 Jul 15; 41(2):139-48. PubMed ID: 15983908
    [Abstract] [Full Text] [Related]

  • 37. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
    Nagai K, Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC.
    J Antimicrob Chemother; 2001 Sep 15; 48(3):365-74. PubMed ID: 11533001
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.